Mon Apr 14 10:40:00 UTC 2025: **Pfizer Stock: A Buy Despite Recent Dip, Analyst Says**
NEW YORK – Despite a recent market downturn and a three-year decline, Pfizer (NYSE: PFE) stock may be undervalued and ripe for investment, according to a recent analysis by The Motley Fool. While the company’s financial performance has slowed since the peak of the COVID-19 pandemic, its robust U.S. manufacturing capacity and strong drug pipeline position it for future growth.
The analysis highlights Pfizer’s extensive U.S. manufacturing network – the largest in the industry – as a key advantage. This allows the company to potentially mitigate the impact of potential future tariffs on pharmaceuticals, unlike competitors who rely heavily on cheaper overseas manufacturing. CEO Albert Bourla emphasized this strategic advantage at a recent conference.
While revenue from its COVID-19 vaccine and treatment has declined, Pfizer’s overall sales grew 7% year-over-year in 2024 to $63.6 billion, exceeding expectations when excluding COVID-related revenue. Strategic acquisitions, particularly the $43 billion purchase of Seagen, have bolstered its oncology portfolio and significantly expanded its drug pipeline, with over 100 candidates in development.
The article points to Pfizer’s low forward price-to-earnings (P/E) ratio of 7.6, significantly lower than the healthcare industry average of 15.8, as further evidence of its undervaluation. Although market timing remains unpredictable, the analyst suggests that current prices present a potentially significant buying opportunity for long-term investors. However, it is noted that Pfizer was not included in The Motley Fool’s list of the 10 best stocks to buy now. The article encourages readers to explore The Motley Fool’s other recommendations.
First Piper 